

Guihua Hou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1058297/publications.pdf>

Version: 2024-02-01

19
papers

231
citations

933447

10
h-index

1058476

14
g-index

20
all docs

20
docs citations

20
times ranked

308
citing authors

#	ARTICLE	IF	CITATIONS
1	1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship. <i>Frontiers in Pharmacology</i> , 2021, 12, 661173.	3.5	49
2	Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E ₂ receptor EP2 subtype. <i>Science Advances</i> , 2021, 7, .	10.3	28
3	TLR5: A prognostic and monitoring indicator for triple-negative breast cancer. <i>Cell Death and Disease</i> , 2019, 10, 954.	6.3	23
4	The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of <i>Helicobacter pylori</i> by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
5	Cyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review). <i>Biomedical Reports</i> , 2014, 2, 775-779.	2.0	16
6	Phosphorylation of the Archaeal Holliday Junction Resolvase Hjc Inhibits Its Catalytic Activity and Facilitates DNA Repair in <i>Sulfolobus islandicus</i> REY15A. <i>Frontiers in Microbiology</i> , 2019, 10, 1214.	3.5	15
7	Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation. <i>Oncotarget</i> , 2016, 7, 1854-1862.	1.8	15
8	TLR5 is a new reporter for triple-negative breast cancer indicated by radioimmunoimaging and fluorescent staining. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8305-8313.	3.6	13
9	Design, Synthesis and Anti-Lung Cancer Evaluation of 1, 2, 3-Triazole Tethered Dihydroartemisinin-Isatin Hybrids. <i>Frontiers in Pharmacology</i> , 2021, 12, 801580.	3.5	13
10	Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, 856-862.	0.6	10
11	CD93 in macrophages: A novel target for atherosclerotic plaque imaging?. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2152-2162.	3.6	6
12	IL-27 R α cells promoted allojection via enhancing STAT1/3/5 phosphorylation. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10756-10767.	3.6	5
13	Non-invasive imaging of Toll-like receptor 5 expression using ¹³¹ I-labeled mAb in the mice bearing H22 tumors. <i>Oncology Letters</i> , 2014, 7, 1919-1924.	1.8	4
14	IL-27 R α : A Novel Molecular Imaging Marker for Allograft Rejection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1315.	4.1	4
15	Radioimmunoimaging of ¹²⁵ I-labeled anti-CD93 monoclonal antibodies in a xenograft model of non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 6413-6422.	1.8	4
16	Down-regulating cyclin-dependent kinase 9 of alloreactive CD4+ T cells prolongs allograft survival. <i>Oncotarget</i> , 2016, 7, 24983-24994.	1.8	4
17	Autophagy in allografts rejection: A new direction?. <i>Biochemical and Biophysical Research Communications</i> , 2016, 471, 572-575.	2.1	2
18	Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 708047.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Anti-migratory effect of rapamycin impairs allograft imaging by 18F-fluorodeoxyglucose-labeled splenocytes. <i>Molecular Medicine Reports</i> , 2016, 14, 2194-2198.	2.4	1